Closing out their program on endometrial carcinoma management, key opinion leaders highlight key novel therapeutic strategies in the evolving treatment landscape.
Robert L. Coleman, MD, and Krishnansu S. Tewari, MD, reflect on data from the GARNET clinical trial of dostarlimab in dMMR recurrent endometrial carcinoma.
Robert L. Coleman, MD, opens discussion on a second patient case and highlights critical aspects of mismatch repair deficient (dMMR) recurrent endometrial carcinoma.
Before closing out their discussion on the first patient case, key opinion leaders on endometrial carcinoma reflect on the optimal selection and sequencing of therapy in pMMR recurrent disease.
Expert panelists provide their perspective on the real-world use of combination lenvatinib + pembrolizumab in patients with MMRp recurrent endometrial carcinoma.
Moderator Robert L. Coleman, MD, spearheads a review of clinical data from KEYNOTE 775, which combined lenvatinib with pembrolizumab in patients with endometrial carcinoma.
Key opinion leaders in the field of endometrial carcinoma management share advice on optimal patient monitoring and the identification of recurrent disease.
Experts Michael J. Birrer, MD, PhD, and Kimberly Halla, MSN, FNP-C, share insight to a typical patient presentation of MMRp recurrent endometrial carcinoma.
Opening its discussion on endometrial carcinoma, a panel of experts led by Robert L. Coleman, MD, reflects on a patient with mismatch repair proficient (MMRp) recurrent disease.
